Trial Profile
A Phase 1 Open-label Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Apr 2023
Price :
$35
*
At a glance
- Drugs Zolbetuximab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Astellas Pharma
- 01 Apr 2023 Results published in the Cancer Science
- 21 Jan 2023 Results of an analysis assessing CLDN18.2 expression and exploratory biomarkers of zolbetuximab alone or with mFOLFOX6 in G/GEJa using data from phase 1 (NCT03528629) and phase 2 (NCT03505320, ILUSTRO Cohorts 1 and 2) studies presented at the 2023 Gastrointestinal Cancers Symposium
- 09 Dec 2021 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI183958).